DexCom price target raised to $106 from $103 at Canaccord

Canaccord raised the firm’s price target on DexCom (DXCM) to $106 from $103 and keeps a Buy rating on the shares. The firm said they reported a good Q1, beating total and US revenue estimates, while short of OUS estimates but showing strong organic growth OUS.